Your browser doesn't support javascript.
loading
Preexposure prophylaxis for men who have sex with men in the Netherlands: impact on HIV and Neisseria gonorrhoeae transmission and cost-effectiveness.
Reitsema, Maarten; Hoek, Albert Jan van; van der Loeff, Maarten Schim; Hoornenborg, Elske; van Sighem, Ard; Wallinga, Jacco; van Benthem, Birgit; Xiridou, Maria.
Afiliação
  • Reitsema M; Department of Epidemiology and Surveillance, National Institute for Public Health and the Environment (RIVM), Bilthoven.
  • Hoek AJV; Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden.
  • van der Loeff MS; Department of Epidemiology and Surveillance, National Institute for Public Health and the Environment (RIVM), Bilthoven.
  • Hoornenborg E; Department of Infectious Diseases, Public Health Service Amsterdam, Amsterdam.
  • van Sighem A; Department of Internal Medicine, Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centers, University of Amsterdam.
  • Wallinga J; Department of Infectious Diseases, Public Health Service Amsterdam, Amsterdam.
  • van Benthem B; Stichting HIV Monitoring, Amsterdam, The Netherlands.
  • Xiridou M; Department of Epidemiology and Surveillance, National Institute for Public Health and the Environment (RIVM), Bilthoven.
AIDS ; 34(4): 621-630, 2020 03 15.
Article em En | MEDLINE | ID: mdl-31895142
ABSTRACT

OBJECTIVES:

To assess the impact of a preexposure prophylaxis (PrEP) programme for high-risk men who have sex with men (MSM), which includes gonorrhoea testing and treatment, on the transmission of HIV and Neisseria among MSM in the Netherlands and the cost-effectiveness of such programme with and without risk compensation (in the form of reduced condom use).

METHODS:

We developed a stochastic agent-based transmission model of HIV and gonorrhoea. We simulated a capped (max 2.5% of MSM) and uncapped (5.5% of MSM in 2018 declining to 3% in 2027) daily PrEP programme for high-risk MSM, with 3-monthly HIV and gonorrhoea testing, with and without risk compensation. Epidemiological outcomes were calculated from the transmission model and used in an economic model to calculate costs, quality-adjusted life-years (QALY), and incremental cost-effectiveness ratios (ICER), over 2018-2027, taking a healthcare payer perspective.

RESULTS:

Without risk compensation, PrEP can lead to a reduction of 61 or 49% in the total number of new HIV infections in 2018-2027, if the programme is uncapped or capped to 2.5% of MSM, respectively. With risk compensation, this reduction can be 63 or 46% in the uncapped and capped programmes, respectively. In all scenarios, gonorrhoea prevalence decreased after introducing PrEP. Without risk compensation, 92% of simulations were cost-effective (of which 52% cost-saving). With risk compensation, 73% of simulations were cost-effective (of which 23% was cost-saving).

CONCLUSION:

A nationwide PrEP programme for high-risk MSM can result in substantial reductions in HIV and gonorrhoea transmission and be cost-effective, even with risk compensation.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Gonorreia / Infecções por HIV / Homossexualidade Masculina / Fármacos Anti-HIV Tipo de estudo: Health_economic_evaluation / Prevalence_studies / Risk_factors_studies Aspecto: Patient_preference Limite: Humans / Male País/Região como assunto: Europa Idioma: En Revista: AIDS Assunto da revista: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Gonorreia / Infecções por HIV / Homossexualidade Masculina / Fármacos Anti-HIV Tipo de estudo: Health_economic_evaluation / Prevalence_studies / Risk_factors_studies Aspecto: Patient_preference Limite: Humans / Male País/Região como assunto: Europa Idioma: En Revista: AIDS Assunto da revista: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Ano de publicação: 2020 Tipo de documento: Article
...